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Abstract Sorting-related receptor with A-type repeats
(SORLA) is an intracellular sorting receptor that directs
cargo proteins, such as kinases, phosphatases, and sig-
naling receptors, to their correct location within the cell.
The activity of SORLA assures proper function of cells
and tissues, and receptor dysfunction is the underlying
cause of common human malignancies, including Alz-
heimer’s disease, atherosclerosis, and obesity. Here, we
discuss the molecular mechanisms that govern sorting of
SORLA and its cargo in multiple cell types, and why
genetic defects in this receptor results in devastating
diseases.
Keywords VPS10P domain receptors  Protein sorting 
Retromer  GGA  Alzheimer’s disease  Obesity
Introduction
Sorting of proteins to their destined location in subcellular
compartments is essential for proper cell function, and
faulty protein sorting will result in cellular dysfunction and
disease. Protein sorting is essential for all cell types, but
particularly challenging in neurons in which cell
compartments of axons and dendrites may be as far away
as 1 m from the soma of motor neurons. Within cells, the
Golgi is the central hub that sorts the bulk of proteins.
Protein sorting proceeds in the trans-most cisterna of this
organelle called the trans-Golgi network (TGN) that con-
sists of an elaborate web of branching tubular membrane
domains. From the TGN, proteins may be targeted to the
apical or basolateral plasma membranes, to the endosomal/
lysosomal system, or to specialized secretory granules for
activity-dependent release. Directed protein trafficking is
mediated by sorting receptors, transmembrane proteins that
interact with cytosolic adaptors at the Golgi membranes to
guide their protein cargo to and from the TGN (reviewed in
[1]).
In recent years, one group of sorting receptors received
particular attention because of their causal involvement in
human diseases, such as Alzheimer’s and Huntington’s
disease, psychiatric disorders, but also atherosclerosis,
dyslipidemia, and diabetes. These sorting receptors are
called VPS10P domain receptors. Initially characterized in
neurons in the brain, VPS10P domain receptors now
emerge as key regulators of intracellular protein sorting
not only in the nervous system but also in many other
tissues as well [2]. Here, we focus on the sorting-related
receptor with A-type repeats (SORLA), a VPS10P domain
receptor that is paradigmatic for the mode of action of
this class of sorting receptors. We describe the molecular
interactions of SORLA with adaptor complexes that
control traffic between TGN, plasma membrane, and
endosomes. We discuss the functional significance of this
trafficking pathway for proper routing of enzymes, growth
factors, and signaling receptors, and why SORLA dys-
function may result in devastating pathologies, including
neurodegeneration, impaired renal ion homeostasis, and
obesity.
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Cell biology of SORLA sorting
SORLA (also known as LR11 or SORL1) was initially
uncovered in the search for receptors that share structural
similarity to the low-density lipoprotein (LDL) receptor, the
main endocytic receptor for uptake of lipid-loaded lipopro-
teins into vertebrate cells. These studies identified a 250-kDa
type 1 transmembrane protein in brain [3] and liver [4] that
contained complement-type repeats and a b-propeller, struc-
tural elements in the LDL receptor required for binding and for
pH-dependent release of ligands, respectively (Fig. 1a). The
ability of SORLA to internalize lipoproteins seemingly sup-
ported the notion of a novel species of lipoprotein receptor
[5, 6]. However, this assumption was questioned by the
presence of additional structural elements in SORLA not
found in the LDL receptor, namely a VPS10P domain and six
fibronectin-type III domains (Fig. 1a). The VPS10P domain
was noteworthy as it was identified earlier in an intracellular
sorting protein in yeast called the vacuolar protein sorting 10
proteins (VPS10P) [7]. VPS10P directs newly synthesized
peptidases from the TGN to the vacuole (the yeast lysosome)
where they act in proteolytic breakdown of internalized pro-
teins. A similar function for SORLA in intracellular protein
sorting in mammalian cell types was supported by the fact that
the bulk of the receptor molecules was present in the Golgi
rather than at the cell surface, a finding that argued against a
role as endocytic receptor [6, 8].
By now, an extensive body of work has substantiated the
relevance of SORLA as an intracellular sorting receptor that
shuttles between TGN, cell surface, and endosomes in neu-
rons and multiple other cell types. SORLA is synthesized as a
pro-receptor containing a 53 amino-acid pro-peptide at the
ultimate amino terminus. This pro-peptide is believed to
block the binding site for ligands in the VPS10P domain, a
major site for interaction with peptide ligands [9, 10].
Removal of the pro-peptide by convertases in the TGN
activates the ligand-binding capability of the receptor [6].
This activation step may be required to prevent premature
binding of ligands to nascent receptor molecules in the
biosynthetic pathway of the cell. Apart from the VPS10P
domain, the cluster of complement-type repeats in SORLA
constitutes another site for ligand recognition [11, 12].
Binding of ligands to the VPS10P domain or the comple-
ment-type repeats is lost at low pH (\5.5) [13], suggesting
ligand interaction to partake in the secretory pathway and at
the cell surface, but to be disrupted in the acidic milieu of late
endosomes. The significance of additional structural elements
in the extracellular domain for receptor functions is less clear.
Based on analogy to other proteins, the fibronectin-type III
domain may be involved in protein–protein interactions [14],
while the b-propeller may facilitate pH-dependent release of
ligands in endocytic compartments [15].
As well as by the ability to recognize distinct ligands
through its luminal domain, the function of SORLA in
protein sorting is determined by information encoded in its
short cytoplasmic tail. This tail domain encodes recogni-
tion motifs for cytosolic adaptors that direct the complex
trafficking path of SORLA between cell surface and vari-
ous intracellular compartments (Fig. 1b). Typically, newly
synthesized SORLA molecules follow the constitute
secretory pathway from the endoplasmic reticulum through
the Golgi to the cell surface, a default route for trans-
membrane proteins that does not require distinct sorting
motifs (Fig. 2). At the cell surface, some SORLA mole-
cules are subject to proteolytic shedding releasing the
soluble ectodomain of the receptor, termed soluble
(s) SORLA [16, 17]. However, most SORLA molecules at
the cell surface remain intact and undergo clathrin-depen-
dent endocytosis guided by the clathrin adaptor protein 2
(AP2) that interacts with an acidic motif D2190-
DLGEDDED in the receptor tail [8]. Internalized receptors
move to the early endosomes from where most receptors
will sort to the TGN to continuously shuttle between TGN
and endosomes thereafter. Retrograde movement of
SORLA from endosomes to the TGN is guided by phos-
phofurin acidic cluster sorting protein 1 (PACS1) that also
Fig. 1 Structural organization of SORLA. a Organization of the
SORLA polypeptide is shown, indicating the main structural elements
and their documented functions. The VPS10P domain and the cluster
of complement-type repeats serve as major ligand-binding sites in the
luminal receptor domain. The b-propeller interacts with the molecular
chaperone MESD to facilitate folding of the receptor polypeptide, and
it may be involved in pH-dependent release of bound ligands in acidic
endosomal compartments. b Amino-acid sequence of the cytoplasmic
receptor tail highlighting three main binding motifs for cytosolic
adaptors, termed FANSHY, the acidic motif (DDLGEDDED), and the
GGA-binding site (DDVPMV). GGA, Golgi-localizing, c-adaptin ear
homology domain, ARF-interacting protein; MESD, mesodermal
development deletion interval; VPS10P, vacuolar protein sorting 10
proteins. a adapted from [43]
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binds to the acidic cluster [18], and by the multimeric
adaptor complex retromer that binds to the F2172ANSHY
tail motif [19, 20]. Anterograde sorting of SORLA from the
TGN to endosomes is mediated by the monomeric clathrin
adaptors GGA1 and GGA2 (Golgi-localizing, c-adaptin ear
homology domain, and ARF-interacting proteins) that
interact with the D2207DVPMVIA element in the SORLA
tail [18, 21, 22]. Finally, binding of the adaptor protein
AP1 to the acidic tail motif may aid in anterograde as well
as retrograde sorting of SORLA [8]. The shuttling of pro-
tein cargo between TGN and endosomes likely constitutes
the major trafficking route taken by SORLA in neurons.
However, some studies also report the ability of SORLA to
move ligands from endosomes to the cell surface guided by
the sorting nexin family member (SNX) 27 [23], or from
endosomes to lysosomes, potentially sorted by GGA3
[24, 25]. The complex trafficking path for SORLA has
mainly been elucidated in established cell lines. However,
recent studies in mouse models expressing mutant SORLA
variants lacking individual adaptor binding sites have
substantiated this model in the brain by documenting
impaired anterograde sorting in receptor mutants lacking
the GGA-binding site [25] and impaired retrograde sorting
in mutants unable to interact with PACS1 [26] or retromer
[25].
SORLA controls amyloidogenic processes
in the brain
Given the predominant expression of SORLA in the brain
and its complex trafficking path in neurons, major efforts
have been focused on identifying the protein cargo sorted
by this receptor and its relevance for brain (patho)physi-
ology. These studies have highlighted an important role for
SORLA in control of amyloidogenic processes in the brain
and as a major risk factor for Alzheimer’s disease (AD).
Central to the pathology of AD is the amyloid precursor
protein (APP), a type-1 transmembrane protein expressed
in many cell types, including neurons. In a naturally
occurring process, APP is broken down into various pro-
teolytic fragments, including the amyloid-b peptides (Ab),
peptides of 37–43 amino-acid length that encompass part
of the transmembrane, and extracellular domains of APP.
Amyloid-b peptides, notably Ab42, are considered main
culprits in neurodegenerative processes as they exhibit a
tendency to aggregate to neurotoxic oligomers and senile
plaques, pathological features causative of neuronal dys-
function and cell loss in AD patients (reviewed in [27]).
Amyloidogenic processing requires endocytosis of APP
molecules from the cell surface and delivery to endosomes
whereby proteolytic breakdown to Ab occurs [28–30]. As
it turns out, SORLA acts as a sorting receptor for APP that
shuttles internalized precursor molecules from endosomes
back to the TGN to decrease production of Ab [18, 31, 32].
Binding of APP proceeds through the cluster of comple-
ment-type repeats in SORLA that forms a 1:1
stoichiometric complex with the luminal domain of APP
[11, 12, 33]. Overexpression of SORLA in cells reduces
Ab formation [18, 31, 32, 34], while loss of expression
accelerates Ab production and senile plaque deposition
[35, 36], documenting a protective function for SORLA in
AD progression. The interaction of SORLA and APP is
blocked by signaling through b-adrenergic receptors via a
yet unknown mechanism, resulting in impaired Golgi
retrieval and in increased endosomal accumulation of APP
[37]. In line with the presumed sorting path of the receptor,
prevention of APP processing depends on the ability of
SORLA to move retrogradely from endosomes to the TGN
Fig. 2 Intracellular trafficking path for SORLA. Nascent SORLA is
an inactive pro-receptor (pro-SORLA) that is activated by proteolytic
removal of an amino-terminal pro-peptide in the TGN, resulting in
transfer of the active receptor (SORLA) through the constitutive
secretory pathway to the cell surface. Some receptor molecules at the
cell surface are subjected to ectodomain shedding, resulting in release
of the extracellular receptor domain. Ectodomain shedding disrupts
the ability of SORLA to act as a sorting receptor, but may serve to
produce a soluble receptor fragment termed soluble (s)SORLA that
acts as a signaling molecule. Still, most SORLA molecules at the cell
surface remain intact and undergo clathrin-dependent endocytosis
facilitated by the clathrin adaptor protein (AP) 2. The bulk of
internalized receptors move from endosomes back to the TGN to
continuously shuttle between TGN and endosomal compartments
thereafter. Adaptors GGA1 and GGA2 guide anterograde movement
of SORLA from the TGN to endosomes, whereas PACS1 and the
retromer complex facilitate retrograde sorting from endosomes back
to the Golgi. AP1 may be involved in bi-directional sorting. As
alternative routes, SORLA may sort from endosomes to the cell
surface (aided by adaptor SNX27) or to lysosomes (aided by GGA3).
Figure adapted from [43]. AP, adaptor protein; GGA, Golgi-
localizing, c-adaptin ear homology domain, ARF-interacting protein;
PACS1, phosphofurin acidic cluster sorting protein 1; SNX27, sorting
nexin family member 27
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and is lost in receptor mutants that cannot interact with
retromer [25] or PACS1 [26]. As well as by sorting APP,
SORLA has also been shown to reduce the amyloidogenic
burden by sorting of newly produced Ab peptides to
lysosomes for catabolism [13]. This activity depends on the
interaction of Ab with a recognition site in the VPS10P
domain of SORLA [10] and on the ability of the receptor to
interact with GGAs to move in an anterograde fashion from
the TGN to endocytic compartments [25].
Taken together, the ability of SORLA to sort APP and Ab
likely represents major mechanisms, whereby this receptor
reduces the amyloidogenic burden and delays progression of
neurodegeneration. This hypothesis received strong support
from genetic studies in AD patients that identified gene vari-
ants in SORL1, the gene encoding SORLA, as being
associated with the risk of the sporadic form of AD
[34, 38, 39]. Some of these sequence variants have been shown
to impair efficiency of SORL1 transcription [34, 40, 41] or
translation [42], in line with low levels of SORLA being
disease promoting in patients and mouse models (reviewed in
[43]). Furthermore, a missense mutation in SORL1, that dis-
rupts its ability to bind Ab, has been identified in a family with
the autosomal dominant form of AD [44].
SORLA in neurotrophin signaling
Protein cargo sorted by SORLA in neurons is not restricted
to APP and its processing products, but also encompasses a
number of neurotrophin receptors, cell surface proteins that
transmit trophic signals to support growth and survival of
neurons. Specifically, SORLA acts as a sorting factor for the
tropomyosin-related kinase receptor (TrkB), the receptor for
brain-derived neurotrophic factor (BDNF). SORLA facili-
tates trafficking of TrkB between synaptic membranes and
the cell soma, a step critical for BDNF signal transduction
into cells [45]. Loss of SORLA results in impaired neuritic
transport of TrkB and in a blunted response to BDNF [45].
Intriguingly, SORLA is also a downstream target of BDNF
with receptor gene transcription being induced almost
10-fold by BDNF signaling in neurons [41, 46]. These data
suggest a positive feedback loop, whereby BDNF enhances
trophic signaling through induction of SORL1, the gene
encoding the sorting receptor for TrkB.
Another trophic pathway modulated by SORLA acts
through glial cell-line-derived neurotrophic factor (GDNF)
that promotes survival of distinct populations of central and
peripheral neurons, such as midbrain dopaminergic neu-
rons and spinal motor neurons. SORLA interacts with
GDNF to increase its regulated secretion from cells [47]. In
addition, SORLA interacts with GFRa1, the co-receptor for
GDNF [48]. SORLA facilitates internalization of GFRa1/
GDNF complexes from the plasma membrane, resulting in
lysosomal catabolism of GDNF but cell surface recycling
of GFRa1. This sorting route provides an efficient pathway
for clearance of GDNF from the extracellular space and
counteracts consequences of excessive GDNF signaling,
such as hyperactivity and reduced anxiety (as seen in mice
lacking SORLA) [48]. Finally, SORLA also impacts sig-
naling through a heterodimeric neurotrophic cytokine
called cardiotrophin-like cytokine:cytokine-like factor 1
(CLC:CLF-1) [49]. Specifically, SORLA interacts with the
CLF-1 moiety to facilitate internalization of the cytokine in
complex with the ciliary neurotrophic factor receptor
(CNTFR) a. SORLA-dependent endocytosis is required for
neurotrophic signaling through CLC:CLF-1, but it also
downregulates signal reception by directing ligand and
receptor to lysosomal degradation [49].
The cell biology of SORLA-dependent sorting of neu-
rotrophins and their receptors, and the implication of
cytosolic adaptors in this process, still awaits further
investigation. However, the ability of this receptor to
impact pathways both for trophic support but also of
amyloidogenic insult to neurons makes this sorting path-
way an important target in control of neurodegenerative
processes in patients.
SORLA in renal ion homeostasis
While major attention has been focused on the relevance of
SORLA for protein sorting in neurons, other studies have
uncovered important roles for this protein in non-neuronal cell
types, as well. Thus, SORLA is abundantly expressed in the
thick ascending limb (TAL) of Henle’s loop, a distal segment
of the renal nephron responsible for water and ion homeostasis
[50, 51]. Lack of SORLA expression in epithelial cells of the
TAL results in failure to properly reabsorb sodium and chlo-
ride, a defect attributed to the inability of these cells to activate
the major sodium transporter in the distal nephron Na–K-Cl
cotransporter 2 (NKCC2) [51]. As it turns out, SORLA con-
trols the phospho-regulation of NKCC2 by interacting with
both the Ste-20-related proline-alanine-rich kinase (SPAK)
[51] and the calcineurin phosphatase [52] that carry out
phosphorylation and dephosphorylation of NKCC2, respec-
tively. These findings suggest SORLA-mediated sorting of
kinases and phosphatases as a regulatory process in modula-
tion of renal ion balance.
SORLA in vascular cell migration
and atherosclerosis
Atherosclerosis, or thickening of the artery wall, is a major risk
factor for cardiovascular morbidity and mortality, including
myocardial infarction and stroke. Atherosclerosis is caused by
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excessive accumulation of lipids in macrophages in the vessel
wall (foam cells) and by the proliferation of intimal smooth
muscle cells. Jointly, these processes contribute to the for-
mation of fibrous plaques that may obstruct the vessel lumen.
Interestingly, Sorl1 has been mapped as a pro-atherogenic
locus in mice [53]. The relevance of SORLA for atheroscle-
rotic processes was further supported by correlating
circulating levels of the shedded ectodomain sSORLA
(indicative of full-length receptor levels in tissues) with
intima-media thickness in subjects with coronary artery dis-
ease [54] or acute coronary syndrome [55]. Currently, there
are two main hypotheses how SORLA impacts atherosclerotic
plaque formation. One model suggests a role for SORLA in
control of plasma triacylglyceride levels through regulation of
lipolysis. Triacylglyceride-rich lipoproteins are highly pro-
atherogenic particles. Their turnover is determined by
hydrolysis of triacylglycerides to free fatty acids through
lipoprotein lipase (LPL) in the circulation. SORLA traffics
newly synthesized LPL molecules from the TGN to lyso-
somes, reducing the amount of the enzyme being secreted by
cultured cells [56]. In addition, SORLA mediates the endo-
cytosis of apoA-V, an activator of LPL [57, 58]. Modulation of
LPL activity through clearance of apoA-V is supported by the
loss of SORLA binding in an apoA-V variant found in indi-
viduals with severe hypertriglyceridemia [59]. Potentially,
either through control of LPL or apoA-V levels, SORLA may
inhibit lipolysis and raise the levels of pro-atherogenic
lipoprotein particles in the circulation.
An alternative model suggests a more direct role for
SORLA in atherosclerotic processes in the vessel wall. It is
based on the ability of SORLA to stimulate proliferation
and migration of intimal smooth muscle cells (SMC) and
monocytes, processes that accelerated intimal thickening
and atherosclerotic plaque formation [60–63]. Potentially,
the stimulation of SMC migration by SORLA works
through modulation of cell surface expression of the
urokinase receptor (uPAR) [64, 65]. The uPAR is a gly-
cosylphosphatidyl inositol-anchored receptor for urokinase,
a protease that activates plasminogen to plasmin, which, in
turn, breaks down the extracellular matrix. Binding of
urokinase to uPAR on the surface of cells increases their
proteolytic potential and facilitates migration. The ability
to regulate surface exposure of uPAR is seen for full-length
SORLA but also for sSORLA, suggesting both cell
autonomous and non-autonomous modes of action [65, 66].
SORLA is a risk factor for obesity
Genome-wide association studies not only confirmed the
relevance of SORL1 as a genetic risk factor for sporadic
AD [38] but also revealed a surprising association of this
locus with metabolic traits (e.g., obesity and waist
circumference) in humans and mouse models [67, 68]. In
addition, loss of SORLA expression in mice with targeted
Sorl1 disruption is protected from diet-induced obesity,
suggesting a so far unknown function for this receptor in
metabolic regulation [69, 70]. Recent studies in transgenic
mouse models shed light on potential modes of receptor
action, albeit proposing distinct roles for SORLA and
sSORLA in this context. In a study by Whittle and col-
leagues, sSORLA was shown to impair thermogenesis in
mice by binding to bone morphogenetic protein (BMP)
receptors and inhibiting BMP/TGF b signaling in adipo-
cytes [69]. Thermogenesis is the process of heat
production from metabolic fuel and a driving force for
consumption of body lipid stores by brown adipose tissue.
Mice genetically deficient for SORLA are protected from
diet-induced obesity because of enhanced thermogenesis
in adipose tissue, providing an explanatory model for the
association of SORL1 with obesity in the human popula-
tion [69].
An alternative model to explain the role of SORLA in
energy homeostasis entails intracellular sorting of the
insulin receptor (IR) [70]. One of the actions of insulin
signaling in adipocytes is the downregulation of lipolysis.
This mechanism reduces energy production from break-
down of lipid stores in a state of sufficient energy supply
from carbohydrates. Cellular signal transduction proceeds
through binding of insulin to the IR on the surface of target
cells and subsequent endocytosis of receptor and hormone
complexes. Internalization serves two purposes. First, it
delivers receptor-ligand complexes to endosomes, a pre-
requisite for signal transduction. Second, it moves
receptor-ligand complexes to lysosomal compartments for
catabolism, a mean to downregulate signal reception. In a
process reminiscent of APP sorting in neurons, SORLA
interacts with internalized IR molecules in endosomes and
shuttles them back to the TGN. Retrograde trafficking
reduces lysosomal catabolism and increases the fraction of
IR molecules recycled back to the cell surface. SORLA-
dependent recycling sensitizes adipocytes for insulin signal
reception and enhances the impact of insulin on blockade
of lipolysis. Consequently, overexpression of SORLA in
adipose tissue of mice inhibits lipolysis and promotes the
fat mass gain, while loss of the receptor expression
increases lipolysis rate and protects animals from obesity
and secondary metabolic complications [70].
In obese human subjects, the levels of SORLA in adi-
pose tissue [70] and those of sSORLA in the circulation
[69] positively correlate with the body mass index.
Although the exact mode of action in adipose tissues as
humoral factor or as sorting receptor still awaits further
clarification, all current data support the significance of
SORL1 as genetic risk factor of obesity in the human
population.
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Outlook: SORLA dysfunction as an explanatory
model for comorbidities?
Studies on seemingly unrelated disease entities have
converged on SORLA as a sorting receptor for multiple
ligands in organs, such diverse as the brain, the kidney,
or adipose tissue. These observations raise the intriguing
possibility that SORLA (dys)function may explain some
of the comorbidities commonly seen in the human
population as exemplified for AD and type II diabetes
(T2D). T2D, a disease characterized by lack of respon-
siveness of cells to insulin (insulin resistance), is one of
the major risk factors for sporadic AD [71]. As well as
in peripheral tissues, such as muscle, liver, and fat,
insulin signaling is also widespread in neurons in the
brain, where it modulates central control of metabolism
but also behavior and memory [72–74]. In AD patients,
brain insulin signaling is impaired, partially due to
reduced levels of the hormone [75] and abnormal
intracellular sequestration of the IR in neurons caused by
Ab [76, 77]. Conversely, alerted levels of insulin sig-
naling in a diabetic state may impact Ab metabolism by
changing rates of production and clearance as suggested
by studies in vitro and in rodent models [78, 79]. Cur-
rently, the mechanistic link between brain insulin
resistance and amyloidogenic processes is a matter of
intense debate and the reader is referred to excellent
recent reviews in this subject ([80]). A role for SORLA
in insulin signaling in neurons has not been documented
yet. However, low levels of the receptor are likely to
result in decreased neuronal sensitivity to the hormone
as shown for adipocytes previously [70]. Although quite
speculative at present, low levels of receptor expression
in carriers of SORL1 risk alleles may thus cause both
central insulin resistance and increased amyloidogenic
burden, and prove to be an explanatory model for the
link between neurodegenerative and metabolic diseases
that warrant further exploration.
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